Develops the POWDOSE dosing system for precise, weight-based dosing of oral solid dosage forms.

AbbatiaLabs

Lausanne (CH)New on Amplifa

LausanneCompany headquarters (CH)

2-step mechanismRing for dose pre-setting, turn knob for dispensing

up to 30Full dispenses per fill

RSD < 7 %Dosing accuracy test criterion (±25 % of the mean)

0.001 gPrecision of the test scale (KERN F1, 240 g capacity)

About AbbatiaLabs

AbbatiaLabs is a company specializing in drug delivery devices, based in Lausanne, Switzerland. It develops and markets POWDOSE, a patented dosing and primary packaging system for oral solid dosage forms that enables exact dose titration by the end user. The two-part device allows the desired dose to be pre-set via a ring and the medicinal product to be dispensed via a turn knob; it is suitable for multiparticulate formulations, minitablets and granulate-based medicines. The housing consists of a limited number of environmentally friendly, sustainable polymers; an integrable desiccant protects the medicine from moisture. In cooperation with pharmaceutical partners, including Adare Pharma Solutions (Diffucaps technology), co-development programs are carried out to adapt dose ranges. Target indications include pediatric weight-based dosing, neurology, ADHD, cardiovascular diseases and antibiotics.

Site: Lausanne, Switzerland
Processes: Development and manufacture of dosing/primary packaging systems for oral solid dosage forms, Injection molding – as expertise of the CTO for medical device development, Compatibility with multiparticulates, minitablets and granulate-based medicines; testing for, Development of a dosing and primary packaging system (POWDOSE) for oral solid dosage forms, Co-development programs for adapting dose ranges, Dosing technology for dose titration (weight-based dosing), Integration of desiccant in the device, Compatible with multiparticulates, minitablets and granulates
Materials: Environmentally friendly sustainable polymers (device housing), Diffucaps Sugar Spheres size 30, Diffucaps Sugar Spheres size 18/20, Sustainable Polymers, Integrable Desiccant, Diffucaps Sugar Spheres size 30 (500–700 µm), Diffucaps Sugar Spheres size 18/20 (800–1,000 µm)
Certificates: Dosing accuracy testing (RSD < 7 %, ±25 % criterion)
Industries: Pharmaceutical Industry, Biotech, Drug Delivery / Combination Products, Pediatrics, Neurology, ADHD

01
Device development (engineering)
02
Injection-molding-compatible design / medical device development
03
Manufacture of prototypes/test devices
04
Dosing accuracy testing (scale, test protocol)
05
Co-development with pharmaceutical partners

Materials & Processes

Sustainable Polymers

Environmentally friendly, sustainable polymers for the POWDOSE device housing with a limited number of components.

Desiccant

Integrable Desiccant

Desiccant integrable in the device protects the medicine from moisture and increases stability.

Diffucaps 30

Diffucaps Sugar Spheres size 30 (500–700 µm)

Polymer-membrane multiparticulates for testing dosing accuracy in the POWDOSE system.

Diffucaps 18/20

Diffucaps Sugar Spheres size 18/20 (800–1,000 µm)

Larger granulate for validating the dosing device across different formulations.

Locations

Lausanne

Company headquarters, device development

Lot size: Prototypes (4 test devices in the evaluation project)
Materials: Sustainable polymers

Calibrated precision scale KERN F1 (240 g, 0.001 g)

Components

**POWDOSE dosing device**Plastic injection molding (development) · Pharma/Drug Delivery

Inside the production

Industries

Pharmaceutical IndustryBiotechDrug Delivery / Combination ProductsPediatricsNeurologyADHDCardiovascularAntibiotics

Processes & technical limits

Processes	Tolerance	Max. part	Weight	Lot size	Materials
Development and manufacture of dosing/primary packaging systems for oral solid dosage formsEngineering	–	–	–	–	sustainable polymers, polymer membranes (Diffucaps multiparticulates), sugar sphere granules (500–700 µm, 800–1,000 µm)
Injection molding – as expertise of the CTO for medical device developmentPlastics	–	–	–	–	polymers
Compatibility with multiparticulates, minitablets and granulate-based medicines; testing forTesting	RSD < 7 % or ±25 % of the mean (test criterion)	–	–	–	Diffucaps sugar spheres size 30 (500–700 µm), Diffucaps sugar spheres size 18/20 (800–1,000 µm)

1 Anlagen & Maschinen

Machine	Manufacturer / model	Quantity	Working area	Year built	Site
Calibrated precision scale (testing equipment)	KERN F1	–	Capacity 240 g, precision 0.001 g	–	–

Additional services

Development of a dosing and primary packaging system (POWDOSE) for oral solid dosage formsCo-development programs for adapting dose rangesDosing technology for dose titration (weight-based dosing)Integration of desiccant in the deviceCompatible with multiparticulates, minitablets and granulates

Reference customers

Adare Pharma Solutions (cooperation, Diffucaps®)

Quality

Dosing accuracy is tested with a calibrated KERN F1 precision scale (240 g capacity, 0.001 g precision); the test criterion is RSD < 7 % or deviation of all doses within ±25 % of the mean, with reference to the European Pharmacopoeia 2.9.40.

Evidence	Lausanne
Dosing accuracy testing (RSD < 7 %, ±25 % criterion)

History

2019
Thierry Jomini co-founded Anteris Helvetia, a consultancy for drug delivery devices; acquired by Kymanox in 2023.
2024
Stéphane Baronnet joined AbbatiaLabs and heads device development.
2025
Publication on the evaluation of the POWDOSE system with Adare Pharma Solutions' Diffucaps technology (ONdrugDelivery Issue 173).